Volastra Therapeutics, Inc., is developing novel therapies to treat cancer. Launched from the laboratory of Dr. Lewis Cantley, along with Drs. Olivier Elemento and Samuel Bakhoum, Volastra has identified the mechanisms by which CIN drives the formation and proliferation of solid tumors. Following initial evidence that a patient’s CIN status is prognostic and that CIN alters cellular and immune response mechanisms and leads to worse overall survival in mouse models, the company is discovering mechanisms and pathways by which CIN modulates disease to develop novel therapeutics.
Location: United States, New York
Employees: 11-50
Total raised: $116M
Founded date: 2019
Investors 5
| Date | Name | Website |
| 19.07.2021 | Vida Ventu... | vidaventur... |
| - | Droia Onco... | droiaventu... |
| - | Quark Vent... | quarkventu... |
| 11.07.2025 | B Capital ... | bcapgroup.... |
| - | Catalio Ca... | cataliocap... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 07.03.2023 | Series A | $60M | - |
| 06.04.2021 | Seed | $44M | - |
| 11.02.2020 | Seed | $12M | - |
Persons 16
| Date | First Name | Last Name | Title | Location | |||
| - | Rumin | Zhang, PhD | - | linkedin.c... | - | r****g@vol... | - |
| - | Sarah | Bettigole | Vice Presi... | linkedin.c... | - | s********e... | - |
| - | Yazen | Jmeian | Director, ... | linkedin.c... | - | i**o@volas... | - |
| - | Reka | Letso | Laboratory... | linkedin.c... | - | r****o@vol... | - |
| - | Diane | Tager | Chief Oper... | linkedin.c... | - | d****r@vol... | - |
| - | Jonathan | Havel | Senior Sci... | linkedin.c... | - | j****l@vol... | - |
| - | Rachel | Zolot Schw... | - | linkedin.c... | - | r****t@vol... | - |
| - | Albert | Swiston | - | linkedin.c... | - | a******n@v... | - |
| - | Nazario | Bosco | - | linkedin.c... | - | N****O@vol... | - |
| - | Alan | Chiu | Scientist ... | linkedin.c... | - | a***u@vola... | - |
Show more
Mentions in press and media 14
| Date | Title | Description |
| 23.01.2024 | Two more pharmas practice their Accent, invest in $75M series C round | Accent Therapeutics has reeled in investments from two more pharmaceutical companies as part of a $75M series C, the latest validation for the RNA drug developer. Bristol Myers Squibb and Johnson & Johnson’s investment arm, JJDC, partic... |
| 07.03.2023 | Volastra Therapeutics Secures $60M in Series A Funding | Volastra Therapeutics, a New York-based clinical stage cancer biotechnology company focused on exploiting chromosomal instability (CIN), raised $60M in Series A funding. The round was led by Polaris Partners and ARCH Venture Partners, Eli L... |
| 07.03.2023 | Volastra Therapeutics In-Licenses Clinical Stage KIF18A Inhibitor and Secures $60 Million in Series A Funding to Further Advance Cancer-Focused Pipeline | - |
| 07.03.2023 | ARCH leads Volastra $60 million financing round | - |
| 29.06.2022 | 'Science doesn't care' about markets: Arch raises nearly $3B amid tough times for biotechs | Arch Venture Partners is out to prove there’s still money for the taking for up-and-coming biotechs, raising nearly $3 billion for its latest fund amid a tumultuous bear market. The company was relatively vague on what the money for its twe... |
| 21.03.2022 | Volastra Therapeutics Announces Drug Discovery Collaboration with Bristol Myers Squibb | Bristol Myers Squibb to leverage Volastra’s proprietary CINtech platform to discover and develop oncology drug candidates |
| 06.04.2021 | Volastra Therapeutics Expands Seed Funding to $44M | Volastra Therapeutics, a NYC-based biotechnology company developing novel therapies for the prevention and treatment of metastatic cancer, extended its original $12m seed round to a total of $44m. New investors Vida Ventures and Catalio Cap... |
| 06.04.2021 | Volastra Therapeutics : Extends Seed Financing to $44 Million to Advance Drug Discovery Programs to Prevent Cancer Metastasis | Volastra Therapeutics, a biotechnology company developing novel therapies for the prevention and treatment of metastatic cancer, today announced the extension of its original $12 million seed round to a total of $44 million. New investors V... |
| 06.04.2021 | Volastra Therapeutics Scores $12M Seed Round | NEW YORK, NY, Volastra Therapeutics today announced the extension of its original $12 million seed round to a total of $44 million. >> Click here for more funding data on Volastra Therapeutics >> To export Volastra Therapeut... |
| 11.02.2020 | Volastra Therapeutics Raises $12M in Seed Financing | Volastra Therapeutics, a NYC-based biotechnology company developing novel therapies for the treatment of metastatic cancers, raised $12m in funding. The round was led by Polaris Partners with participation from DROIA Oncology Ventures, the ... |
Show more